Press Releases

Press Releases

Press Releases

December 14, 2017
CAMBRIDGE, Mass. , Dec. 14, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the
December 7, 2017
CAMBRIDGE, Mass. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that
November 15, 2017
FDA Prescription Drug User Fee Act goal date set for August 30, 2018 CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious
November 13, 2017
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced
November 7, 2017
CAMBRIDGE, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that
November 6, 2017
Submitted marketing authorization applications in the US, EU and Canada for volanesorsen in FCS  Expanded leadership team to support global commercial launch of volanesorsen        Conference Call Webcast Monday, November 6 , 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass. , Nov.
October 31, 2017
Akcea expects to initiate Phase 2b in patients with hypertriglyceridemia with established cardiovascular disease by the end of this year CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
October 27, 2017
CAMBRIDGE, Mass. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics , Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, announced today that it has
October 23, 2017
Webcast scheduled for Monday, November 6 at 4:30 p.m. Eastern Time CAMBRIDGE, Mass. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious
October 16, 2017
Full results from global IN-FOCUS study presented at NORD Rare Diseases and Orphan Products Breakthrough Summit CAMBRIDGE, Mass. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs